LB1798 Tolerance induction in a preclinical pemphigus vulgaris (PV) mouse model utilizing desmoglein 3 peptides-conjugated nanoparticles
Christoph Hudemann(Philipps University of Marburg), Holger Garn(Philipps University of Marburg), Michael Hertl(Universitätsklinikum Gießen und Marburg), Daria Krzikalla(Information Today (United States)), Sarah Fleischer, Reinaldo Digigow(Information Today (United States)), B. Metzler, Rüdiger Eming(Philipps University of Marburg)
Cited by 0
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|379
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
|Journal of the European Academy of Dermatology and Venereology|2020|332
Updated<scp>S2</scp>K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)
|Journal of the European Academy of Dermatology and Venereology|2022|247